Differential Activation of Hepatic Invariant NKT Cell Subsets Plays a Key Role in Progression of Nonalcoholic Steatohepatitis

Igor Maricic, Idania Marrero, Akiko Eguchi, Ryota Nakamura, Casey D. Johnson, Suryasarathi Dasgupta, Carolyn D. Hernandez, Phirum Sam Nguyen, Austin D. Swafford, Rob Knight, Ariel E. Feldstein, Rohit Loomba and Vipin Kumar

*J Immunol* 2018; 201:3017-3035; Prepublished online 15 October 2018; doi: 10.4049/jimmunol.1800614
http://www.jimmunol.org/content/201/10/3017

---

Supplementary Material
http://www.jimmunol.org/content/suppl/2018/10/14/jimmunol.1800614.DCSupplemental

References
This article cites 110 articles, 26 of which you can access for free at:
http://www.jimmunol.org/content/201/10/3017.full#ref-list-1

---

Why *The JI*? Submit online.
- **Rapid Reviews! 30 days** from submission to initial decision
- **No Triage!** Every submission reviewed by practicing scientists
- **Fast Publication!** 4 weeks from acceptance to publication

*average

---

Subscription
Information about subscribing to *The Journal of Immunology* is online at:
http://jimmunol.org/subscription

Permissions
Submit copyright permission requests at:
http://www.aai.org/About/Publications/JI/copyright.html

Email Alerts
Receive free email-alerts when new articles cite this article. Sign up at:
http://jimmunol.org/alerts

---

*The Journal of Immunology* is published twice each month by
The American Association of Immunologists, Inc.,
1451 Rockville Pike, Suite 650, Rockville, MD 20852
Copyright © 2018 by The American Association of Immunologists, Inc. All rights reserved.
Print ISSN: 0022-1767 Online ISSN: 1550-6606.
Differential Activation of Hepatic Invariant NKT Cell Subsets Plays a Key Role in Progression of Nonalcoholic Steatohepatitis

Igor Maricic,1* Idania Marrero,*,1 Akiko Eguchi,† Ryota Nakamura,† Casey D. Johnson,† Suryasarathi Dasgupta,*, Carolyn D. Hernandez,*, Phirum Sam Nguyen,*, Austin D. Swafford,‡ Rob Knight,†,‡ Ariel E. Feldstein,†,‡ Rohit Loomba,*,†,‡,§ and Vipin Kumar*,†,‡,¶

Innate immune mechanisms play an important role in inflammatory chronic liver diseases. In this study, we investigated the role of type I or invariant NKT (iTNK) cell subsets in the progression of nonalcoholic steatohepatitis (NASH). We used α-galactosylceramide/CD1d tetramers and clonotypic mAb together with intracytoplasmic cytokine staining to analyze iTNK cells in choline-deficient l-amino acid–defined (CDAA)-induced murine NASH model and in human PBMCs, respectively. Cytokine secretion of hepatic iTNK cells in CDAA-fed C57BL/6 mice altered from predominantly IL-17+ to IFN-γ+ and IL-4+ during NASH progression along with the downmodulation of TCR and NK1.1 expression. Importantly, steatosis, steatohepatitis, and fibrosis were dependent upon the presence of iTNK cells. Hepatic stellate cell activation and infiltration of neutrophils, Kupffer cells, and CD8+ T cells as well as expression of key proinflammatory and fibrogenic genes were significantly blunted in Jo18−/− mice and in C57BL/6 mice treated with an iTNK-inhibitory RAR-γ agonist. Gut microbial diversity was significantly impacted in Jo18−/− and in CDAA diet–fed mice. An increased frequency of CXCR3+IFN-γ+T-bet+ and IL-17A+ iTNK cells was found in PBMC from NASH patients in comparison with nonalcoholic fatty liver patients or healthy controls. Consistent with their in vivo activation, iTNK cells from NASH patients remained hypersensitive to ex-vivo stimulation with α-galactosylceramide. Accumulation of plasmacytoid dendritic cells in both mice and NASH patients suggest their role in activation of iTNK cells. In summary, our findings indicate that the differential activation of iTNK cells play a key role in mediating diet-induced hepatic steatosis and fibrosis in mice and its potential involvement in NASH progression in humans. The Journal of Immunology, 2018, 201: 3017–3035.

Nonalcoholic fatty liver disease (NAFLD) is the most frequent chronic liver disease that affects 10–20% of the population in developed countries and is increasing in prevalence with the rise of diabetes and obesity (1–3). NAFLD is characterized by abnormal accumulation of fat within liver or steatosis (nonalcoholic fatty liver [NAFL]) that can progress to severe inflammatory cell infiltration or nonalcoholic steatohepatitis (NASH) accompanied by necrosis and fibrosis that can lead to liver cirrhosis and hepatocellular carcinoma (4). A detailed understanding of the cellular and molecular mechanisms involved in progression from steatosis to fibrosis in NAFLD is lacking, and they are crucial in the development of effective therapeutic approaches to halt this disease.

Different unconventional innate-like T cells, including γδ-T cells, mucosal-associated invariant T (MAIT) cells, and NKT cells, are enriched in liver, where they can play a key role in immune homoeostasis. NKT cells are the major innate-like T cells in the liver of both mice and humans. NKT cells recognize both self and microbial lipids presented by the MHC class I–like molecule CD1d (5). CD1d-restricted NKT cells have been shown to play an important role in inflammatory conditions, including autoimmune and infectious diseases (6–9). NKT cells can be divided in two main subsets, type I or invariant NKT (iTNK) and type II, based upon differences in TCR characteristics and some of the Ags they recognize. Although both...
NKT cell subsets are predominantly NK1.1+ in mouse or CD161+/CD56+ in human, they also share common features in their TCR repertoire (10, 11). Murine iNKT cells express an invariant germline encoded Vα14/Jα18 TCRα-chain paired with a more diverse nongermline TCRβ-chains, including Vβ8.2, Vβ7, and Vβ2, and human iNKT cells express an invariant Vα24/Jα18 paired predominantly with Vβ11. In contrast, type II NKT cells express a relatively more diverse TCR repertoire and appear to be regulatory in nature. Although the semi-invariant TCR in iNKT cells binds to CD1d in a parallel configuration that mainly involves the α-chain, a type II NKT cell TCR contacts its ligand primarily via its β-chain rather than an α-chain, suggesting that the TCR Vβ-chain contributes significantly to Ag fine specificity of type II NKT cells (12). Thus, type II NKT cells use features of TCR binding shared by both iNKT cells and conventional T cells (12, 13). Therefore, both NKT cell subsets display distinct modes of Ag recognition.

One major caveat of the study of NKT cells in inflammatory liver diseases relates to the lack of specific reagents to distinguish between the two major NKT cell subsets and between NKT cells and CD3+CD56+/CD161+ conventional T cells. The most widely used approach involves using the ability of the iNKT cells to recognize the marine sponge–derived glycolipid, α-galactosylceramide (αGalCer) that forms stable CD1d tetramers to identify this subset. For type II NKT cells, there is no universal Ag marker, but we have identified a major subset of type II NKT cells that recognizes a self-glycolipid, sulfatide (13, 14). Thus, quantification of iNKT cells using αGalCer/CD1d tetramers or type II NKT cells using sulfatide or lysophosphatidylcholine/CD1d tetramers, respectively, is crucial to identify each subset and to distinguish them from conventional T cells. For human iNKT cells, a clonotypic Ab (clone 6B11) directed against the human iNKT cell TCR can be used to differentiate them from other T cells (15). We have demonstrated that iNKT cells play a pathogenic role in Ischemia reperfusion injury, Con A–induced hepatitis, and Lieber–DeCarli liquid alcohol diet–induced liver injury, whereas the activation of type II NKT cells following administration with sulfatide or lysophosphatidylcholine induces a dominant anti-inflammatory pathway that prevents liver disease (16–19).

It has been shown that chronic feeding of choline-deficient t–amino acid–defined (CDAA) diet results in steatosis and perisinusoidal/pericellular fibrosis, resembling NASH in humans (20–22). Interestingly, most of the United States population does not meet the recommended intake of choline, and its deficiency is known to exacerbate NAFL and NASH (23–25). In addition, humans with inadequate choline intake have oxidative damage caused by mitochondrial dysfunction and endoplasmic reticulum stress (23). Therefore, it remains unknown whether and/or how different NKT cell subsets can influence the progression from steatosis to fibrosis in a murine model of NASH and in humans. Although recent studies have suggested a potential pathogenic role for NKT cells in diet–induced liver steatosis and fibrosis (26–29), a detailed study of the role of different cytokine-secreting NKT cell subsets and related immune mechanism is lacking.

In this study, we sought to investigate the role of iNKT cell subsets in the development of NASH in a murine model following CDAA diet as well as in PBMCs from NAFLD patients. Our studies revealed the involvement of a key immune mechanism centered on different subsets of iNKT cells mediating progression from steatosis to fibrosis in experimental murine model as well as its potential role in human NAFLD. Activated IL–17– and IL–22–secreting iNKT cells were dominant in liver during the beginning of the steatosis phase, whereas IFN–γ/IL–10–secreting iNKT cells were prevalent later in the disease. In addition, activation of iNKT cells is associated with neutrophils, Kupffer cells (KCs), and CD8+ T cells infiltration and upregulation of several key genes related to inflammation, steatosis, and fibrosis. We also found a similar profile of cytokine secretion by iNKT cells in PBMC from NASH patients and, more importantly, a high frequency of CXCR3+/IFN–γ–expressing iNKT cells in NASH patients. In addition, we found accumulation of plasmacytoid dendritic cells (pDC) into liver following CDAA diet and similar increase of pDC frequency in peripheral blood of NASH patients. Genetic depletion of pDC in BDC2–DTR mice results in inhibition of iNKT activation, suggesting their role in activation of iNKT cells. In addition, the significant increase in the frequency of CXCR3+/IFN–γ–expressing iNKT cells as well as pDC in PBMC from NASH patients compared with healthy controls suggests that they could become potential novel biomarkers in the progression of NASH in humans.

Materials and Methods

Ethics statement

Animal studies were carried out in strict accordance with the recommendations of the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The protocols were reviewed and approved by the Institutional Animal Care and Use Committee of the University of California San Diego (UCSD). Human studies were approved by the UCSD Institutional Review Board. Informed consent was obtained from all study subjects before blood collection.

Mice

Seven–to–ten-week-old male C57BL/6 (B6) and B6 transgenic mice (CLEC4C–HBEFGF/56Cln3/BDC2–DTR) (JAX stock no. 014176) were purchased from The Jackson Laboratory, C57l/6 and Jo18 mice were originally generated by Van Kaer and Taniguchi (30, 31), respectively, and were kindly provided initially by Dr. M. Kronenberg (La Jolla Institute for Allergy and Immunology, La Jolla, CA). All mice were maintained in specific pathogen-free conditions.

Patients and healthy individuals

The study included 23 diagnosed patients with NAFLD: five patients with NAFL and 18 patients with NASH. In parallel, 19 healthy volunteers with no history of liver pathologic condition were obtained from iXCells Biotechnologies (San Diego, CA). Diagnosis of NAFLD was based on the hepatic biopsies and the severity of tissue damage was evaluated on the basis of NAFLD activity score and fibrosis based on the NAFLD fibrosis risk score at the UCSD NAFLD Translational Research Unit. All patients with NASH had significantly higher NAFLD activity scores and NAFLD fibrosis scores compared with NAFL patients.

Murine NASH model

B6 and Jo18+− mice were maintained on either a CDAA (20% protein, 35% carbohydrate, and 45% fat, without choline; Dyets, Bethlehem, PA) or a normal diet (29% protein, 58% carbohydrate, and 13% fat; LabDiet, St. Louis, MO) for 20 wk. For time-course studies, B6 mice were fed CDAA diet for 1 wk or 1, 2, 3, or 4 mo. CDAA diet has been extensively shown to induce steatohepatitis and fibrosis, which pathologically replicate the histological features of steatohepatitis and fibrosis observed in human NASH.

Isolation of liver mononuclear cells

To obtain mononuclear cells (MNCs), livers were harvested and pressed through a Falcon 70–μm cell strainer (Corning), and suspended in HyClone High Glucose DMEM Medium (Thermo Fisher Scientific, Waltham, MA). Liver MNCs were washed, and the cell pellet was resuspended in 35% Percoll solution (GE Healthcare Life Sciences, Marlborough, MA) containing 100 U/ml heparin and centrifuged at 2000 rpm at room temperature for 15 min. The supernatant was carefully removed and erythrocytes were disrupted by RBC Lysis Buffer (MilliporeSigma, Burlington, MA). The cells were washed with DMEM supplemented with 2% of FBS, and passed liver MNCs cells were counted with a hemocytometer using trypan blue and resuspended in FACS buffer (0.02% sodium azide, 2% FBS in PBS).

Isolation of PBMC

Blood samples were taken by venipuncture into sterile, EDTA tubes. PBMCs were isolated by density gradient centrifugation on Ficoll–Hypaque.
Flow cytometry analysis and intracellular staining

Data were collected on a FACScanto flow cytometer (BD Biosciences, BD, San Diego, CA) at the Flow Cytometry Research Core Facility (Veterans Affairs San Diego Healthcare System, San Diego, CA) and analyzed with FlowJo v10 software (TreeStar, Ashland, OR). Mouse Abs (clones) were used as follows: anti-TCRβ (H57-597), anti-CD3 (145-2C11), anti-CD4 (GK1.5), anti-CD8α (53-6.7), anti-CD19 (1D3), anti-CD45RB (HI100-1D3), anti-CD11c (BU22), anti-CD14 (HCD14), anti-CD56 (5.1H11), anti-CD11b (M1/70), and anti-CD69 (H1.2F3) from BD; anti-CD25 (7D4), anti-CD38 (H12G10), anti-CD69 (1D3), anti-CD103 (2E7) (from BioLegend, San Diego, CA), and anti–IL-7Rα (2B1) from BD. Cells in culture were harvested on day 10 after stimulation with PMA (10 ng/ml) and ionomycin (500 ng/ml) (MilliporeSigma) for 6 h with addition of BD GolgiPlug containing brefeldin A at the start of culture. Cells were first stained for cell surface markers, then fixed and permeabilized using Cytofix/Cytoperm Fixation Buffer and stained for the following fluorochrome-labeled Abs: anti–IFN-γ (XMG1.2), anti–IL-4 (1D4-2B8.2), anti–IL-10 (JES5-16E3), anti–IL-13 (eBio13A), anti–IL-17 (eBio17B7), and anti–IL-22 (IL22JOP) (from eBioscience, San Diego, CA). Human Abs were used as follows: anti–CD3 (UCHT1), anti–CD19 (SJ25-C1), anti–CD4 (RPA-T4), anti–CD123 (CD1d42), and anti–CD45 (H300) from BD; anti–Vγ2Vδ1 TCR (6B11) from eBioscience; anti–CXCR3 (49801) from R&D Systems; anti–CD123 (CD1d42), and anti–CD11c (BioLegend); and LIVE/DEAD Fixable Aqua Dead Cell Stain Kit from Thermo Fisher Scientific. For constitutive detection of cytokines and transcription factors in human iNKT cells, no in vitro stimulation was used; instead, PBMCs were stained directly for cell surface markers and then fixed and permeabilized as before and incubated with the following mAbs: anti–IFN-γ (XMG1.2), anti–IL-17A (eBio6D4DEC17), anti–IL-22 (22URT1), anti–IL-10 (JES5-9D7), and anti–T-bet (4B10) from eBioscience; and anti–IL-4 (MP4-25D2) and anti–TNF-α (MAb11) from BD.

Tazarotene treatment

Tazarotene (Tocris Bioscience, Ellisville, MO) was injected i.p. at a dose of 300 μg/mouse twice per week over the same period of CADA feeding. Control mice were injected with DMSO/PBS. Tazarotene was initially diluted in 10% DMSO at 100 mg/ml and further diluted with PBS prior injection.

In vivo depletion of pDC

BDC2A-DTR mice and littermates were depleted of pDC by injecting 200 ng of diphtheria toxin (DT) (MilliporeSigma) on day −2 and −1 of CADA diet. Similar DT treatment was made on day 3 and 6 after starting CADA diet. Mice were sacrificed on day 8 and pDC depletion was verified by flow cytometry.

In vitro PBMC stimulation

PBMCs (2 × 10^6/well, duplicate) were cultured into 96-well plate in 250 μl of RPMI 1640 medium supplemented with 10% FBS, 1% l-glutamine, 1% penicillin/streptomycin, and 40 U/ml of human rIL-2 (PeproTech, Rocky Hill, NJ) with 100 ng/ml of GalCer or without stimulation. The cells were cultured for 10 d at 37°C in an atmosphere containing 5% CO₂. Supernatants of cell cultures were collected on day 4 and stored at −80°C until analysis. For cytokine analysis, cells in culture were harvested on day 10 after stimulation and stained for analysis of iNKT cells by FACS as above. Fold expansion of iNKT cells was calculated by dividing frequencies of iNKT cells in PBMC cultures containing GalCer during 10-d expansion by the frequencies on day 0 without stimulation. Secretion of cytokines in the supernatants was determined using the BD CytoFluor Bead Array Human Th1/Th2/Th17 Cytokine Kit (BD).

Histology

Liver tissues were fixed in 10% formaldehyde solution and kept at room temperature until use. H&E staining of tissue sections (5-μm) was performed at the UCSD Neuroscience Core for Microscopy. Steatosis and liver fibrosis were assessed with Sirius Red/Fast Green staining. Myeloperoxidase (MPO) staining was performed using anti-MPO Ab-1 rabbit polyclonal Ab (Thermo Fisher Scientific). All pictures were taken using the NanoZoomer 2.0-HT Slide Scanning System (Hamamatsu, Japan) and quantified on ImageJ software (National Institutes of Health).

Microbiome analysis

Stool collection. Three to four fresh fecal pellets were collected individually from mice (each mouse was placed in a confined place to avoid cross-contamination) using sterile cotton swabs into individually labeled sterile 0.6-ml Eppendorf tube. Samples were collected during 2 d from BALB/c mice of mixed age and sex that were maintained in our own facility for a minimum of 2–3 wk to 8 mo. Following collection, tubes containing stool samples were stored at −80°C until analysis. For CADA diet-fed groups, mice were age and sex matched and fecal pellets were collected similarly but at the end of the experiment.

16S rRNA gene sequencing. DNA was extracted using the PowerSoil DNA Extraction Kit (MO BIO Laboratories) according to Earth Microbiome Project standard protocols (32) (http://www.earthmicrobiome.org/emp-standard-protocols/). PCR primer targeting the V3-V4 region of the 16S rRNA genes was performed with the 515F/806R primers, using the protocol described in Walters et al. (33). Amplicons were barcoded and pooled in equal concentrations for sequencing. The ampiclon pool was purified with the UltraClean PCR Clean-Up Kit (MO BIO Laboratories), and 2 × 150–bp sequencing was performed in the MiSeq System sequencing platform at the Institute of Genomic Medicine (UCSD).

16S rRNA sequencing data processing and analysis. Raw sequencing data were deposited in Qiita and processed via QIIME v1.9.1 (34) in Qiita using parameters for demultiplexing and quality control recommended by Bokulich et al. (35). Forward reads were trimmed to 150 bp and then processed with deblur (36), a de novo sub–Operational Taxonomic Unit picking method (37). The resulting sOTUs were inserted into the GreenGenes tree (37) and assigned taxonomy via SATE-Enabled Phylogenetic Placement using q2-fingerprinting (39) and Unweighted and Weighted UniFrac distances (40–42) were computed for each experimental group, and then results were visualized in EMPor (43, 44). The sequencing data presented in this article have been submitted to the Qiita study (https://qiita.ucsd.edu/study/description/10781).

RNA, DNA, RT-PCR, and real-time PCR analysis

Total RNA was isolated from liver tissues using a PureLink RNA Mini Kit (Ambion, Thermo Fisher Scientific). RNA was quantified using NanoDrop 2000c spectrophotometer (Thermo Fisher Scientific) and reverse transcribed using RevertAid First Strand cDNA Synthesis Kit (Ambion). To detect mRNA of Vα14Jα281 gene, 5 μg of total RNA were reverse transcribed and subjected to a nested PCR as previously described (45) using the following primer pairs: for first-round PCR, Vα281, forward, 5-TAAGCACAGCACGTGCACAT-3; reverse, Vα281c, 5-GGCCAGTTGGTTGGTTCACT-3; for nested PCR, Vα14/Jα281, forward, 5-TAAGCACAGCACGTGCACAT-3; reverse, Vα281, 5-CATAGCGTGAGTTCCCACT-3; for nested PCR, Vα281a, forward, 5-TAAGCACAGCACGTGCACAT-3; reverse, Vα281, 5-CATAGCGTGAGTTCCCACT-3. Real-time PCR was performed using KAPA SYBR Fast Master Mix (Thermo Fisher Scientific) on a StepOnePlus Real-Time PCR System (Applied Biosystems) with specific primer pairs. Data were analyzed using the ΔΔ cycle threshold method for each normal diet–fed wild-type mouse. Statistical analyses were performed using GraphPad Prism v7 software (GraphPad Software). For all analyses, data were presented as mean ± SEM. For comparison between two groups, unpaired t test for mouse data or two-tailed Mann–Whitney U test for human data were applied. For comparison between three groups (i.e., frequency of iNKT as well as cytokine secretion or transcription factor expression in human PBMCs), one-way ANOVA with Tukey correction was applied. For all analyses, p values were indicated as follows: *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, and ****p ≤ 0.0001.
Results
Activation and differential cytokine secretion profiles of iNKT cells in a diet-induced NASH model

Because chronic feeding of CDAA diet results in liver damage resembling NASH in humans (20–22), we investigated whether progression of diet-induced steatosis to fibrosis is associated with the alterations in the cytokine secretion profile of iNKT cells in liver. Liver MNCs derived from B6 mice maintained on standard normal diet or CDAA diet for 1 wk or 1, 2, 3, or 4 mo were analyzed using αGalCer/CD1d tetramers and intracellular cytokine-based flow cytometry approach. The results showed that IL-17− and IL-22−/−iNKT cells (NKT17) as well as IL-10−/−iNKT cells (NKT10) (TCRβ+/NK1.1+/αGalCer/CD1d-tet) increased significantly during progression of steatosis, reaching a peak at 3 mo of CDAA diet as compared with normal diet–fed B6 mice (Fig. 1A, Supplemental Fig. 1). However, there was no significant increase in IL-17− and IL-22−/−conventional T cells (TCRβ+/NK1.1+/αGalCer/CD1d-tet) at these time points (Supplemental Fig. 2). Interestingly, IFN-γ−, IL-4−, and IL-13−/−iNKT cells (NKT1/NKT2) increased significantly much later during steatosis/fibrosis compared with mice fed normal diet (Fig. 1A, Supplemental Fig. 1). At this later stage following CDAA diet, even conventional T cells significantly produced IFN-γ, but not IL-4 (Supplemental Fig. 2). In summary, the cytokine secretion profile of iNKT cells skewed from predominantly NKT17− to NKT1/NKT2-like, and it correlates with the progression from steatosis to fibrosis following CDAA diet.

Because iNKT cells can downregulate their TCR following chronic stimulation, we compared hepatic iNKT cells between B6 mice fed CDAA diet versus normal diet using αGalCer/CD1d tetramer staining. The results revealed a significant decrease in the tetramer staining of iNKT cells in mice fed CDAA diet compared with normal diet–fed mice (Fig. 1B). We next investigated whether chronic activation of iNKT cells also leads to downregulation of cell surface expression of NK1.1 in addition to TCR. As shown in Fig. 1C, NK1.1 expression was also significantly downregulated in iNKT cells after CDAA diet in comparison with the normal diet.

To further examine that the reduced tetramer staining results from TCR downmodulation, but not from deletion of iNKT cells following chronic activation, we used a semiquantitative RT-PCR approach to analyze the Vα14-Jα18 TCR transcript expression. As expected, the relative quantity of hepatic Vα14-Jα18 PCR product was not decreased, but significantly increased in mice fed CDAA diet compared with normal diet–fed mice (Fig. 1D). Collectively, our data indicate that chronic activation of hepatic iNKT cells is associated with cytokine profile changes and downregulation of both cell surface NK1.1 and invariant TCR during CDAA diet–induced hepatic steatosis and fibrosis.

iNKT cell–deficient Jα18−/− mice are protected from diet-induced hepatic steatosis and fibrosis

To further investigate the role of iNKT cells in the pathogenesis of NASH, iNKT cell–deficient Jα18−/− and B6 mice were fed normal diet or CDAA diet. As shown in Fig. 2A, CDAA diet significantly increased body and liver weight in both B6 and Jα18−/− mice compared with normal diet. Liver weight was significantly reduced in Jα18−/− mice compared with B6 mice. But, epididymal adipose tissue weight did not differ significantly between B6 and Jα18−/− mice following CDAA diet. However, alanine ami-notransferase levels and triglycerides were significantly reduced in Jα18−/− mice compared with B6 mice (Fig. 2B). More importantly, CDAA diet resulted in significant liver damage as indicated by marked steatosis, hepatocyte ballooning, and collagen deposition compared with normal diet–fed B6 mice (Fig. 2C), but Jα18−/− mice had significantly less liver damage than B6 mice. These results indicate that mice lacking iNKT cells (Jα18−/−) were significantly protected from steatosis and fibrosis following CDAA diet, suggesting a pathogenic role of iNKT cells in NASH progression in mice.

To determine whether hepatic stellate cell (HSC) activation is also influenced by iNKT cells following CDAA diet, we assessed α-SMA expression by immunohistochemistry in liver sections from CDAA-fed B6 and Jα18−/− mice. Our results show that α-SMA–positive areas were significantly reduced in Jα18−/− liver compared with B6 (Fig. 2D). Consistent with this, α-SMA expression levels, measured via α-SMA Western blot, were also reduced in Jα18−/− liver compared with B6 following CDAA diet (Fig. 2E). Accordingly, quantitative real-time RT-PCR analyses confirmed that α-SMA transcripts were significantly reduced in Jα18−/− liver compared with B6 mice (Fig. 2F). Furthermore, other key fibrogenic genes like TIMP-1, collagen (COL1) and connective tissue growth factor (CTGF) showed significantly reduced expression in CDAA-fed Jα18−/− mice in comparison with B6 mice (Fig. 2F). These results indicate a key role for iNKT cells in diet-induced HSC activation, steatosis, and fibrosis in liver.

Reduced liver inflammation in Jα18−/− mice following CDAA diet

Next, we examined whether hepatic inflammatory pathways are involved in protecting Jα18−/− mice from diet-induced steatosis and fibrosis. Indeed, CDAA feeding of Jα18−/− mice resulted in a significant reduction of hepatic neutrophil infiltration, analyzed by MPO staining compared with CDAA-fed B6 mice (Fig. 3A). Moreover, the expression level of several key inflammatory genes, including TNF-α, IL-6, KC, and MIP-2, as well as genes related to inflammasome activation like NLRP3 and IL-1α was significantly reduced in Jα18−/− liver compared with B6 following CDAA diet (Fig. 3B). However, genes involved in gluconeogenesis or lipid metabolism did not differ between Jα18−/− and B6 mice following CDAA diet except for downregulation of PEPCK in Jα18−/− mice (Fig. 3B). These results suggest that diet-induced liver inflammation and steatohepatitis are reduced in the absence of iNKT cells, confirming their critical role in mediating diet-induced NASH.

A RAR-γ agonist treatment inhibits effector function of iNKT cells and protects mice from CDAA-induced steatosis and fibrosis

We have recently shown that an agonist of the RAR-γ, tazarotene, specifically inhibits iNKT cells, but not type II NK cells or conventional T cells, and significantly protects mice from alcoholic liver disease and carbon tetrachloride (CCL4)–induced fibrosis (18). To determine whether functional inhibition of iNKT cells protects mice from diet-induced liver injury, CDAA-fed B6 mice were treated twice a week i.p. with tazarotene (300 μg/mouse) or DMSO/PBS. As shown in Fig. 4A, tazarotene treatment significantly blunted CDAA-induced increase in body, liver, and epididymal adipose tissue weight as compared with untreated mice. More importantly, tazarotene treatment significantly reduced steatosis, collagen deposition, and HSC activation following CDAA diet (Fig. 4B). Next, we investigated whether suppression of liver disease results from the inhibition of iNKT cells in tazarotene-treated animals. We determined the function of iNKT cells in both control and treated groups of mice by measuring proliferative response and cytokine secretion after in vitro stimulation with αGalCer. As shown in Fig. 4C, both proliferation and cytokine secretion by iNKT cells were significantly inhibited following tazarotene treatment. Additionally, we found that functional inhibition of iNKT cells was not consequence of reduced numbers of iNKT cells in tazarotene-treated mice as shown by similar
FIGURE 1. Differential activation and cytokine secretion profiles of hepatic iNKT cells in a diet-induced NASH model. (A) Wild type B6 mice were maintained on standard normal diet (ND) or were fed CDAA diet for 1 wk or 1, 2, 3, or 4 mo. Liver MNCs from each experimental group were stimulated in vitro with PMA and ionomycin for 6 h in the presence of GolgiPlug. Cells were stained with anti-TCRβ, anti-NK1.1, and αGalCer/CD1d tetramer before they were fixed, permeabilized, and stained with anti–IFN-γ, anti–IL-17, anti–IL-22, anti–IL-10, anti–IL-4, and anti–IL-13 mAbs. iNKT cells were identified as double TCRβ- and αGalCer/CD1d tetramer–positive cells (TCRβ+/αGalCer/CD1d tetramer+) in the NK1.1+ gate. Cytokine-secreting cells were gated on iNKT cells. Bar graphs show the percentage of iNKT cells secreting IFN-γ, IL-17, IL-22, IL-10, IL-4, and IL-13 in liver of ND- or CDAA diet–fed B6 mice for the indicated time points. Each group included three mice. (B) Representative dot plots of iNKT cells in (Figure legend continues)
numbers of αGalCer/CD1d-tetramer^+ cells and Vα14-Jα18 PCR products in livers of both groups of animals (Fig. 4D). Overall, these data are consistent with the data shown in CDAA-fed Jα18^-/- mice. Thus, both genetic deficiency as well as functional inhibition of iNKT cells leads to the inhibition of diet-induced hepatic steatosis and fibrosis.

**Hepatic infiltration by CD8^+ T cells and macrophages following CDAA diet is dependent on iNKT cells**

Recent data have suggested an important role of hepatic CD8^+ T cells and KCs in murine models of steatosis and fibrosis (28, 46, 47). Next, we determined the role of iNKT cells in hepatic infiltration of CD8^+ T cells in diet-induced liver disease. As expected, CDAA diet significantly increased the frequency of CD8^+ T cells in liver MNCs compared with normal diet (Fig. 5A). We found that the hepatic infiltration of CD8^+ T cells in CDAA-induced liver damage was significantly decreased in Jα18^-/- mice as compared with B6 mice (Fig. 5A).

Because inflammatory macrophages also play a significant role in liver injury, we investigated whether CDAA diet promoted hepatic macrophage infiltration. We followed three distinct subsets of proinflammatory macrophages within liver: KCs, monocytes (Mos), and Mo-derived macrophages gated on CD45^+ F4/80^+ cells as described before (48). Indeed, the frequency of hepatic KC was significantly increased in CDAA-fed B6 mice compared with normal diet-fed B6 mice (Fig. 5B); however, the frequency of Mos and Mo-derived macrophages did not differ between B6 mice feeding CDAA diet or normal diet (Fig. 5B).

To further confirm that the effects on CD8^+ T cells and KC mediated by CDAA diet were dependent on functional iNKT cells, B6 mice maintained on CDAA diet for 20 wk were treated with tazarotene (300 μg/mouse) as before. Tazarotene treatment significantly reduced the frequency of both CD8^+ T cells and KC in liver of CDAA-fed B6 mice as compared with untreated mice (Fig. 5C). These results confirm the key role of iNKT cells in mediating liver infiltration by CD8^+ T cells and KC, consistent with our results in CDAA-fed Jα18^-/- mice.

**iNKT cells from NASH patients are activated and secrete proinflammatory cytokines**

We next sought to determine whether there was evidence of a similar change in the frequency and cytokine profile of circulating iNKT cells in patients with NAFLD as we observed in the murine model of NASH. We first compared the frequency of iNKT cells in peripheral blood between patients with NAFLD (five patients with NAFL and 18 patients with NASH) and 19 healthy controls using a mAb that recognize the invariant CDR3 loop of the human canonical Vα24Jα18 TCR a-chain (clone 6B11) (15) in a multiparameter flow cytometry approach to specifically identify human iNKT cells (Fig. 6A). The selective labeling of iNKT cells was validated by αGalCer/human CD1d tetramer staining that shows equivalent frequencies (data not shown). The frequency of circulating iNKT cells was not significantly different between groups. However, NASH patients exhibited high frequency of circulating iNKT cells (0.34 ± 0.18% versus 0.1 ± 0.03% in healthy controls and versus 0.08 ± 0.05% in NAFL patients) (Fig. 6B). We next examined the functionality of iNKT cells in NAFLD patients and healthy controls by measuring the spontaneous production of IFN-γ, IL-4, IL-17A, IL-22, IL-10, and TNF-α as well as the expression of CXCR3 and T-bet. Compared with both NAFL patients and healthy controls, iNKT cells from NASH patients secreted significantly more IFN-γ, as measured by geometric mean fluorescence intensity (MFI; 679.4 ± 130.1 versus 183.2 ± 30.1 in healthy controls and versus 171.3 ± 69.3 in NAFL patients), than NAFL patients and healthy controls (Fig. 6C, first panel). This was consistent with the analysis of the transcription factor T-bet, which was also highly expressed by iNKT cells from NASH patients compared with healthy control (MFI; 9763 ± 2017 versus 2458 ± 330.3 in healthy controls) (Fig. 6C, second panel). Consistent with a proinflammatory profile, iNKT cells from NASH patients expressed significantly more CXCR3 compared with iNKT cells from both NAFL patients and healthy controls (MFI: 1422 ± 194.4 versus 559.4 ± 74.6 in healthy controls and versus 550.8 ± 59.1 in NAFL patients) (Fig. 6C, third panel). IL-4 secretion was not significantly different in iNKT cells from NASH or NAFL patients and healthy controls (Fig. 6C, last panel). IL-4 secretion was also not significantly different in iNKT cells from NASH or NAFL patients and healthy controls (Fig. 6C, last panel). Furthermore, 55% of NASH patients (10 out of 18) had a population of iNKT cells that produce more IFN-γ than IL-4 (p < 0.001, Fisher test), whereas 87.5% of healthy controls (14 out of 16) had a population of iNKT cells that constitutively secrete more IL-4 than IFN-γ (p = 0.0083, Fisher test) (data not shown).

Additionally, iNKT cells from NASH patients significantly secreted more IL-17A compared with healthy controls (MFI: 293.6 ± 116.6 versus 108.1 ± 20.9) (Fig. 6D). However, when the level of liver fibrosis was considered, patients with advance fibrosis (Fibrosis score 2–4) had lower levels of IL-17A and higher levels of IFN-γ compared with patients with fibrosis score ≤1 (data not shown). Moreover, iNKT cells from NASH patients secreted similar amounts of IL-22, TNF-α, and IL-10 compared with iNKT cells from healthy controls (Fig. 6D). These data suggest that iNKT cells from NASH patients are more activated and proinflammatory as defined by higher expression of CXCR3, T-bet, IL-17A, and IFN-γ.

It is interesting that conventional CD3^-CD4^- CD8^- T cells were significantly increased in peripheral blood of NASH patients compared with healthy controls (67.6 ± 2.6% versus 59.6 ± 2.2%), and consequently, the CD4^-/CD8^- ratio was also significantly increased in NASH patients; however, the frequency of CD8^+ T cells was not different between NASH patients and healthy controls. NAFL patients showed similar trend as NASH patients, but the difference did not reach statistical significance (data not shown).

Interestingly, we detected a subset of iNKT cells that coexpress IFN-γ and CXCR3 (IFN-γ/CXCR3^- iNKT cells) significantly increased in NASH patients compared with healthy controls (47.64 ± 4.73% versus 18.78 ± 3.2%) (Fig. 6E). Also, IFN-γ/CXCR3^- iNKT cells were significantly increased in NASH patients, but not in healthy controls, compared with IFN-γ/CXCR3^- conventional CD3^+ T cells (CD3^+Vα24Jα18TCR^-) (47.64 ± 4.73% versus 27.15 ± 2.61%) (Fig. 6E). These results indicate that IFN-γ/CXCR3^-
iNKT cells were more prevalent in NASH patients than in healthy controls.

**iNKT cells in NASH patients are chronically activated and hyporesponsive to in vitro stimulation with αGalCer**

Because iNKT cells following chronic activation in vivo can become refractory to subsequent ex vivo stimulation, we determined their ex vivo response to αGalCer in PBMC from NASH patients and compared with those from healthy controls. As shown in Fig. 7A, iNKT cells expansion was significantly decreased in NASH patients. The fold expansion of iNKT cells in the cultures was significantly reduced in NASH patients (25.6 ± 8.5) compared with healthy controls (93 ± 39.3) (Fig. 7B). Consistent with their hyporesponsiveness, the secretion of several cytokines, including IL-6, IFN-γ, IL-17A, and IL-4, after αGalCer stimulation was also significantly reduced in NASH patients compared with healthy controls (Fig. 7C). Collectively, these data further indicate chronic in vivo activation of iNKT cells in NASH progression.

**Dendritic cell subsets are altered and involved in iNKT activation in both murine and human NASH**

Because the liver is enriched in different dendritic cell (DC) subsets that can play a central role in iNKT cell activation, we determined whether they are involved in progression of NASH in a murine model.
model and in NASH patients. We first examined the frequency of pDC (PDCA-1<sup>T</sup>SiglecH<sup>+</sup>) and two major subsets of conventional DCs (cDCs), CD103<sup>+</sup>cDC (CD103<sup>+</sup>CD11b<sup>+</sup>) and CD11b<sup>-</sup>cDC (CD103<sup>-</sup>CD11b<sup>+</sup>), in liver MNCs from B6 mice fed CDAA diet. Interestingly, the pDC population was significantly increased in liver of mice fed CDAA diet compared with normal diet–fed B6 mice (Fig. 8A). In contrast, CD103<sup>+</sup> cDC were significantly decreased in CDAA-fed mice compared with normal diet–fed mice, whereas CD11b<sup>-</sup> cDC were not affected significantly (Fig. 8B).

These changes suggest that DC subsets infiltrate into liver differentially during CDAA diet–induced liver injury. Importantly, CD1d surface expression on pDC was similar between B6 mice fed CDAA or normal diet (Fig. 8C). Next, we investigated whether pDC infiltration into liver influenced the activation of hepatic iNKT cells following CDAA diet. To examine pDC role in downregulation of αGalCer/CD1d tetramer<sup>+</sup> iNKT cells, we used transgenic BDCA2-DTR mice, in which pDCs can be specifically depleted with DT. Thus, BDCA2-DTR mice and littermates (transgene negative) were injected with DT as described, and liver MNCs were analyzed by FACS. We found that DT-induced pDC depletion resulted in a significant inhibition of the downregulation of tetramer<sup>+</sup> cells in BDCA2-DTR mice, but not in littermates, following CDAA diet (Fig. 8D). These results indicate that pDC play an important role in CDAA-induced activation and iNKT TCR downregulation.

Next, we determined whether the DC populations are also affected in NASH patients and whether there is any similarity with the murine data. Therefore, we analyzed the frequency in peripheral blood of NASH patients and healthy controls of pDC (CD123<sup>+</sup>CD11c<sup>-</sup>) and two subsets of myeloid DCs (mDCs): CD141<sup>high</sup> mDC, which seem to be the human counterpart of mouse CD103<sup>+</sup> cDC, and CD1c<sup>+</sup> mDC, which appear to be related to mouse CD11b<sup>-</sup> cDC (Fig. 8E). Consistent with our data in a murine model of NASH, the pDC population was significantly increased in peripheral blood from NASH patients compared with healthy controls (11.44 ± 2.08% versus 3.86 ± 1.17%) (Fig. 8E, bottom). In contrast, the frequency of CD141<sup>high</sup> (1.05 ± 0.22% versus 2.1 ± 0.31%) and CD1c<sup>+</sup> (13.46 ± 2.58% versus 28.5 ± 5.53%) mDCs was significantly reduced in NASH patients compared with healthy controls (Fig. 8E, bottom). These results indicate that these pDC and mDC subsets are altered in peripheral blood of NASH patients and may play a role in NASH.

**Altered gut microbiota in Ja18<sup>-/-</sup> mice and CDAA diet–fed mice**

Previous reports have suggested that gut microbiota could potentially have an impact on inflammation in NAFLD (49, 50); we next analyzed the V4 region of the 16S rRNA genes (32) in stool samples to assess whether the protection in iNKT cell–deficient mice (Ja18<sup>-/-</sup>) is related to the differences in microbial diversity. Because the microbiome in Ja18<sup>-/-</sup> and CDAA-treated mice was unknown, we performed a detailed characterization of the composition in our experiments. We found significant differences in the composition of the community between Ja18<sup>-/-</sup> and B6 mice, with greatly increased α diversity in Ja18<sup>-/-</sup> mice as measured by Faith PD (Kruskal–Wallis q = 9.28 × 10<sup>-7</sup>, Fig. 9A) (39). In addition, both strains showed significant and dramatic separation in principal coordinates analysis (PCoA) space of unweighted
FIGURE 4. Treatment of B6 mice with a RAR-γ agonist inhibits effector function of iNKT cells and protects mice from CDAA-induced steatosis and fibrosis. B6 mice maintained on CDAA diet for 20 wk were subjected to i.p. injection of tazarotene (300 μg/mouse) twice per week or left untreated. (A) Body, liver, and epididymal adipose tissue weight in B6 mice untreated or treated with tazarotene following CDAA diet are shown. Each point represents an individual mouse. Each group included 10 mice. (B) Representative H&E, Sirius Red and α-SMA staining of liver sections from CDAA-fed B6 mice untreated or treated with tazarotene. Photomicrographs were prepared at original magnification ×100. Bar graphs show the quantification of Sirius Red–positive area (left) and α-SMA–positive areas (right) in the indicated groups. (C) Bar graphs show proliferative response (stimulation index) and cytokine secretion (IFN-γ, TNF-α, IL-2, IL-4, IL-6, IL-10, and IL-17) in splenocytes from untreated (control) and (Figure legend continues)
When comparing between groups at the phylum level, there were an increased proportion of Proteobacteria and Cyanobacteria in \( \text{Jo}18^- /^- \) mice as well as Deferrribacteres and TM7, which were not detected in B6 mice (Fig. 9C). Similar results were previously reported in the microbiota analysis of CD1d\(^- /-\) mice (53). Only Verrucomicrobia was significantly decreased in \( \text{Jo}18^- /^- \) mice as compared with B6 mice (Fig. 9C). At the genus level, there was an increased proportion of 17 bacterial genera, including Bacteroides, Lactobacillus, Mucispirillum, and Prevotella in \( \text{Jo}18^- /^- \) mice (Fig. 9D). Interestingly, these four genera have been associated with CD1d\(^- /-\) mice (53), suggesting that the lack of NKT cells may enable these groups organisms to occupy a greater fraction of the mouse microbiome. \( \beta \)- and \( \delta \)-proteobacteria have also been reported to be associated with CD1d\(^- /-\) mice (53), and we observed that the \( \beta \)-proteobacteria genus Zoogloe for \( \delta \)-proteobacteria genera Desulfovibrio were present at higher proportion in \( \text{Jo}18^- /^- \) mice than in B6 mice. Several previously unreported genera were also present at an increased proportion in \( \text{Jo}18^- /^- \) mice, including Helicobacteraceae family genera, Odoribacter, AF12 (family Rikenellaceae), Candidatus Arthromitus (family Clostridiaceae), Parabacteroides and F16 family genera (phyllum TM7). In contrast, Bifidobacterium that was previously reported to be associated with CD1d\(^- /-\) mice was present at a decreased proportion in \( \text{Jo}18^- /^- \) mice (53), suggesting that some of the microbiome effects may be specific to the loss of both type NKT cells. Others like Clostridiaceae family genera (order Clostridiales), Coprococcus and Ruminococcus (order Clostridiales, family Lachnospiraceae), Allobaculum, and Akkermansia were also decreased in \( \text{Jo}18^- /^- \) mice (Fig. 9D).

In tazarotene-treated B6 mice fed CDAA diet, there was no significant changes to the \( \alpha \) diversity compared with B6 mice fed a normal diet or B6 mice fed CDAA diet as measured by Faith\( \alpha \) diversity (54). Although a large separation between mice fed a normal diet versus CDAA diet was observed in PCoA space of unweighted UniFrac distances \((q = 0.15 \times 10^{-3})\), PERMANOVA, Fig. 9E, there was a much smaller, although statistically significant, separation between tazarotene-treated and untreated CDAA-fed B6 mice \((q = 0.004\), PERMANOVA, Fig. 9E). Furthermore, our analysis of composition of microbiomes revealed that the only differences between diets at the phylum level were driven by an increased proportion of Actinobacteria and a decreased proportion of Bacteroidetes in CDAA-fed B6 mice regardless of tazarotene treatment (9C). At the genus level, we observed an increased proportion of Desulfovibrio and Clostridiaceae family genera previously reported in CDAA diet-fed mice (54) as well as a significant increase in Allobaculum, Erysipelotrichaceae family genera, and Coriobacteriaceae family genera, which were found only in CDAA-fed mice (Fig. 9D). There was a reduction in the proportion of the microbiome represented by Bifidobacterium S24-7 family genera as well as Rikenellaceae family genera, which were previously reported to be decreased in children affected by NASH (55). However, a robust analysis of tazarotene-treated versus untreated CDAA-fed mice was hampered by low number of mice. Together, these results suggest that profound changes in the gut microbiome result from the CDAA diet, but that the differences in composition of the microbiome observed in \( \text{Jo}18^- /^- \) mice may be driven by events that occur earlier in development rather than as a result of the acute absence of iNKT cells.

**Discussion**

In this study, we have identified a key innate immune mechanism that is crucial for diet-induced progression from steatosis, steatohepatitis, and fibrosis mediated by differential activation and cytokine secretion by hepatic iNKT cell subsets leading to HSC activation, KCs and CD8\(^+\) T cells, and neutrophil infiltration into liver. Thus, in iNKT cell–deficient \( \text{Jo}18^- /^- \) mice, as well as in B6 mice following functional inhibition of iNKT cells, hepatic inflammatory infiltration, steatosis, and fibrosis as well as upregulation of key inflammatory genes are significantly blunted. Interestingly, microbial dysbiosis in the absence of iNKT cells may relate to choline-metabolizing bacteria in CDAA diet–fed mice. Importantly, we also found a significant increase in the frequency of CXCR3\(^+\)/IFN-\( \gamma \) iNKT cells in peripheral blood of NASH patients as compared with healthy controls or NAFL patients. Additionally, rapid accumulation of pDC, but not other DC subsets, into liver occurs following feeding of CDAA diet, and genetic depletion of pDC resulted in significant inhibition of the activation of hepatic iNKT cells. Similarly, NASH patients had a significantly high frequency of pDC in PBMCs compared with healthy controls. Collectively, our data indicate a key role for an immune mechanism mediated by the differentially activated hepatic iNKT cell subsets in progression of NASH.

NKT cells have been shown to be either pathogenic or protective in inflammatory liver diseases (9, 17, 56). Some of the discrepancy related to the role of NKT cells in NAFLD may be due to the presence of different subsets of NKT cells as well as the microbial variability in different animal facilities that has a major impact on NKT cells. In this study, we have used two different approaches to demonstrate a pathogenic role of iNKT cells in not only a murine model but also, importantly, their involvement in NASH in humans. First, \( \text{Jo}18^- /^- \) mice, deficient in iNKT cells but harboring type II NKT cells, are significantly protected from CDAA-induced liver disease (Figs. 2, 3). Secondly, functional inhibition of iNKT cells in tazarotene-treated B6 mice also results in a significant protection from diet-induced hepatic steatosis and fibrosis (Fig. 4). Accordingly, there was similarity in the extent of protection from hepatic damage between tazarotene-treated B6 mice and \( \text{Jo}18^- /^- \) mice. Contribution from other innate-like cells including MAIT cells cannot be completely ruled out, but based upon the published data from others and our laboratory, it is unlikely that they play any significant role in diet-induced liver disease: 1) CD1d\(^- /-\) mice, unlike \( \text{Jo}18^- /^- \) mice (57) that have a full TCR\( \alpha \)–chain repertoire and increased number of MAIT cells (58, 59), are similarly significantly
protected from diet-induced hepatic steatosis and fibrosis (26, 47, 60); 2) anti-CD1d Ab treatment also inhibits diet-induced hepatic disease (19); 3) there is a significant increase in the number of hepatic pDC in the murine model as well as in NASH patients and their important role in activation of iNKT cells; and 4) there is a significant increase in activated proinflammatory iNKT cells in NASH patients in comparison with NAFL patients and healthy subjects. Collectively, our data in murine models and in NASH patients indicate that iNKT cells play an important role in inflammatory liver diseases.

Although, a reduction in iNKT cell numbers has been reported following methionine/choline-deficient or high-fat diets (HFD) as well as in obese ob/ob mice and KK-A(y) diabetic mice (29, 61–65), none of these models have evaluated TCR or NK1.1 down-modulation, specifically on tetramer+ cells. Interestingly, in some cases, proinflammatory activated KC have been shown to induce apoptosis of overactivated iNKT cells following HFD (66). We found that the number of αGalCer/CD1d-tetramer+ cells is progressively reduced in liver of B6 mice following CDAA diet and that the majority of tetramer+ cells had reduced surface expression of NK1.1. However, the intrahepatic mRNA level of the invariant Va14-Ja18 TCR expressed by iNKT cells did not decrease, but rather increased following CDAA diet (Fig. 1). These results suggest that long-term feeding of CDAA diet leads to chronic iNKT cells activation and downmodulation of their surface expression of TCR and NK1.1. It is known that after stimulation with αGalCer or IL-12, iNKT cells can become undetectable because of downmodulation of surface TCR and NK1.1 expression (67–69). Furthermore, progressively increased proinflammatory cytokine secretion by iNKT cells following CDAA diet further indicates their chronic activation.
iNKT cells from NASH patients are activated and secrete proinflammatory cytokines. PBMC were analyzed by multiparameter flow cytometry. iNKT cells were identified using the following gate strategy: first, lymphocytes were gated based on forward light scatter (FSC) and side light scatter (SSC), and singlet live cells were selected. CD19+ cells were excluded, and CD3+ T cells were gated in the CD19- gate. iNKT cells were defined as double CD3- and Va24Ja18 TCR-positive cells (CD3/Va24Ja18 TCR+) in the CD3+ gate and were expressed as percentage of CD3+ T cells. Conventional T cells were identified as CD3-positive and simultaneously as Va24-Ja18 TCR-negative cells (CD3+/Va24-Ja18 TCR-) in the live/CD19- gate.

(A) Representative dot plot of iNKT cells in PBMC from healthy control. Number on dot plot indicate the percentage of iNKT cells within the drawn gate.
(B) Scatter graphs show the cumulative results of the percentage (left) and numbers (right) of iNKT cells in PBMC from healthy controls (n = 19) and patients with NAFL (n = 5) or NASH (n = 18).
(C) Scatter graphs show the geometric MFI of IFN-γ, T-bet, CXCR3, and IL-4 staining of unstimulated iNKT cells in PBMC from healthy controls and patients with NAFL or NASH.
(D) Scatter graphs show the geometric MFI of IL-17A, IL-22, TNF-α, and IL-10 staining of unstimulated iNKT cells in PBMC of NASH patients (n = 8) and healthy controls (n = 10–11).
(E) Representative dot plots of IFN-γ/CXCR3 double-positive cells in the iNKT gate in PBMC of NASH patients (n = 18) and healthy controls (n = 18) (left) and the percentage of IFN-γ/CXCR3 double-positive cells in the conventional CD3+ T cell gate (Conv T) and iNKT gate in PBMC of NASH patients (center) and healthy control (right). Conv T were identified as CD3+/Va24Ja18 TCR+ cells in the CD3+ gate. Each point represents an individual. All data are presented as mean ± SEM. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001 by one-way ANOVA or Mann–Whitney U test.
Another important finding in our study is that IL-17– and IL-22–secreting iNKT cells (NKT17) are dominant early during liver steatosis, whereas IFN-γ– and IL-4– or IL-13–secreting iNKT cells (NKT1/NKT2) cells prevail later during fibrosis following CDAA diet (Fig. 1). Notably, activated IFN-γ– and IL-17A–secreting iNKT cells are also present in high frequency in peripheral blood of NASH patients (Fig. 6) in comparison with those in NAFL patients or healthy controls. Additionally, NASH patients with advanced liver fibrosis had low levels of IL-17A and high levels of IFN-γ compared with patients with less fibrosis (data not shown). Although an important pathogenic role for IFN-γ– and IL-17A–secreting iNKT cells is also present in high frequency in peripheral blood of NASH patients (Fig. 6) in comparison with those in NAFL patients or healthy controls. Furthermore, α-SMA staining as well as expression of genes indicative of fibrosis, including α-SMA, TIMP-1, COL1, and CTGF, was significantly reduced in liver of CDAA-fed Jx18−/− mice. Consistent with our data, methionine/choline-deficient diet also resulted in hepatic iNKT cell stimulation of HSC activation and fibrosis through production of hedgehog protein and osteopontin (26). Similarly, IL-13 secretion by iNKT cells can also promote HSC activation. Accordingly, a profibrotic role for TGF-β/Smad signaling and IL-13 in activation of HSC as well as in upregulation of collagen I and fibrosis-associated genes, like α-SMA and CTGF, in HSC has been shown (78, 79). Furthermore, high serum levels of IL-13 as well as upregulation of IL-13 and IL-13Ra2 expression have been found in activated HSC in liver biopsies from NASH patients (80).

Our data showed that CDAA diet induced a significant increase in liver infiltrating CD8+ T cells and KCs (Fig. 5) that is dependent on iNKT cells because it is reduced significantly in either Jx18−/− mice or following functional inhibition of iNKT cell in B6 mice. We propose that the activation of IFN-γ–secreting iNKT cells results in cross-priming of conventional CD8+ T cells that have been shown to be pathogenic in liver disease following high-fat, high-fat-cholesterol, or choline-deficient high-fat diets (28, 47, 81). Consistent with the potential pathogenic role of CD8+ T cells in liver, increased numbers of infiltrating CD8+ T cells have been found in livers from NASH patients (28, 47, 81).
FIGURE 8. DC subsets are altered and are involved in iNKT activation in both murine and human NASH. (A) Representative contour plots of pDC in liver of B6 mice fed normal diet (ND) or CDAA diet. pDCs were identified as double PDCA-1– and Siglec H–positive cells (PDCA-1+Siglec H+) in the live+CD3+CD45+CD11c+CD11b+B220+ gate. Numbers on plots indicate the percentage of pDC. Bar graph shows the percentage of pDC in B6 mice fed ND (n=8) or CDAA diet (n=6). (B) Representative contour plots of the two major cDC subsets, CD103+ cDC and CD11b+ cDC, in liver of B6 mice fed ND or CDAA diet. The CD103+ cDC subset was identified as CD103-positive and simultaneously CD11b-negative cells (CD103+/CD11b−) in the live+CD3+CD19+CD45+MHC-II+CD11chi gate. The CD11b+ cDC subset was identified as CD11b-positive and simultaneously CD103-negative cells (CD11b+/CD103−) in the live+CD3+CD19+CD45+MHC-II+CD11chi gate. Numbers on plots indicate the percentage of both subsets. Bar graphs show the percentage of CD103+ cDC (left) and CD11b+ cDC (right) in the indicated groups. Each group included three mice. (C) Histogram shows representative CD1d expression on gated pDCs in liver of B6 mice fed ND or CDAA diet. (D) Representative contour plots of pDCs in liver of (Figure legend continues)
Our data in human PBMC indicate that CD8⁺ T cells are not significantly increased in peripheral blood of NASH patients compared with healthy controls and is consistent with the hypothesis that CD8⁺ T cells may have migrated into liver (28, 83). It has been shown that KCs also play a key proinflammatory role in liver damage in NASH via inflammatory cytokines, such as TNF-α, IL-1β, and reactive oxygen species. Thus, depletion of KCs by i.v. injection of liposomal clodronate results in improvement of hepatic steatosis, inflammatory cell infiltration, and metabolic disease (84–87). Collectively, these results indicated that diet-induced HSC activation and hepatic infiltration by CD8⁺ T and KCs is dependent on the presence of activated iNKT cells, suggesting that iNKT cells in collaboration with CD8⁺ T cells and KCs are drivers in the pathogenesis of NASH.

Earlier studies related to the analysis of NKT cells in human NAFLD have caveats because of the use of nonspecific markers like CD3⁺CD56⁺ to identify iNKT cells. In our study, to differentiate NKT cells from other T cells, including type II NKT cells, we used a clonotypic mAb Vo24Ja18 TCR, which specifically identifies iNKT cells. Our data indicated that NASH patients have a significantly higher frequency of activated proinflammatory IFN-γ- and IL-17-secreting iNKT cells in peripheral blood (Fig. 6) in comparison with those from NAFL patients or healthy controls, suggesting their important role in the progression from NAFL to NASH. Consistent with our findings, it has been reported that CD3⁺CD56⁺ NKT-like cells are increased in liver and peripheral blood of NAFLD patients with moderate to severe steatosis (88–90). In addition, Tajiri et al. (91) reported that CD3⁺CD56⁺Vo24⁺ iNKT cells were increased in both liver and peripheral blood of NAFLD patients as the disease activity increased. Consistent with our data, lower frequency of peripheral CD3⁺CD56⁺Vo24⁺ iNKT cells was found in patients with only steatosis and no steatohepatitis (92). Additionally, our data suggest that iNKT cells are chronically activated in vivo in NASH patients as indicated by their hyporesponsiveness to ex vivo stimulation with αGalCer (Fig. 7). Similar ex vivo hyporesponsiveness has been shown in other clinical conditions in which iNKT cells are chronically stimulated, including autoimmune disease and cancer patients (93, 94). Collectively, these data suggest a potentially important role of iNKT cells for progression from NAFL to NASH in humans. Additionally, a subset of IFN-γ⁺CXCR3⁺ iNKT cells is highly represented in NASH patients, suggesting that this could constitute a novel immunological marker for NASH progression.

Our study also indicates a rapid accumulation of pDC, but not other DC subsets in liver of B6 mice, following CDA diet (Fig. 8). Furthermore, selective depletion of pDC in vivo using BDC2-DTR mice (95) leads to a significant inhibition of hepatic iNKT cell activation (97, 106). Consistent with this hypothesis, our preliminary data using Kae1 mice suggest that there is a migration of CD103⁺CD11b⁺ cells, but not CD11b⁺ DC, from the major lymph nodes, draining both small and large intestines into liver in the noninflamed steady state (S. Dasgupta, unpublished observations). A CD103⁺ DC resembling lymphoid tissue–resident CD8⁺ DC has recently been shown to be the major APCs in iNKT cell activation (97, 106). Consistent with this hypothesis, we were unable to investigate pDC depletion effect on NASH progression. Consistently, pDC accumulation in liver and adipose tissue has been recently shown in HFD-induced inflammation (97). We propose that damage of hepatocytes in CDA-fed mice induces the release of mitochondrial DNA (mtDNA), a TLR9 ligand. Because pDC are the major early responders of TLR9, we speculate that mtDNA released from injured hepatocytes affects accumulation of pDC in liver, followed by iNKT activation in a TLR9-dependent manner (15, 98). Recently, hepatic mitochondrial damage has also been reported in NASH patients (99, 100) and increased plasma levels of mtDNA in both HFD-induced murine model as well as in NASH patients have been shown to trigger TLR9 pathway to induce steatosis (101, 102). Notably, rapid accumulation of pDC in the pancreas has been shown to initiate autoimmune diabetes in NOD mice (103). At present, we cannot rule out the importance of other cDC subsets in activation of iNKT cells in our model. It is possible that following chronic feeding of CDA diet, altered gut microbiota could provide the necessary milieu in the gut to facilitate migration of CD103⁺ cDC into liver, where they can cross-prime IFN-γ-⁺iNKT cells and conventional CD8⁺ T cells (104, 105), (S. Dasgupta, unpublished observations). A CD103⁺ DC resembling lymphoid tissue–resident CD8⁺ cDC has recently been shown to be the major APCs in iNKT cell activation (97, 106). Collectively, these data suggest a profound shift in the composition of the gut microbiome (Fig. 9), and the inhibition of iNKT cells largely does not restore the composition to reflect a normal diet nor the Ja18⁻/⁻ mouse composition. As the overall diversity of the gut microbiome in B6 mice is not altered by the CDA diet, an imbalance or dysbiotic state driven by the large changes in nutrient availability may be a driver in the development of CDA diet–induced NASH. Intriguingly, many of the genera that appeared to be increased in CDA-fed mice were identified to be associated with choline consumption and the increased production of trimethylamine, which is converted to the obesogenic compound trimethylamine-N-oxide in the liver (110). Because 16S rRNA sequencing data are compositional, it is not possible to say if the total amount of bacteria in each of these
**FIGURE 9.** Differential microbial diversity in mice lacking functional iNKT cells. Ja18<sup>−/−</sup> (n = 26) and B6 (n = 60) mice were maintained on normal diet (ND). B6 mice maintained on CDAA diet for 20 wk were subjected to i.p. injection of tazarotene (300 μg/mouse) twice per week (n = 8) or left untreated (n = 5). All groups were housed in separate cages. Genomic bacterial DNA was isolated from fecal samples and the V4 region of 16S rDNA was amplified and sequenced. (**A**) Box-plot of Faith α PD for each of the experimental groups; bars indicate the interquartile range. (**B**) Discrimination of mice groups based on PCoA of UniFrac distance. Red, B6, ND; blue, B6, CDAA diet; green, B6, CDAA + Taz; Orange, Ja18<sup>−/−</sup>, ND. (**C**) Summary of the average representation of bacterial phyla detected in these samples. (**D**) Summary of the average representation of bacterial genera detected in these samples. (**E**) PCoA of Ja18<sup>−/−</sup> versus B6 mice with and without CDAA diet and tazarotene treatment. Red, B6, ND; blue, B6, CDAA diet; orange, B6, CDAA + Taz.
groups is increased or if others are proportionately decreased, but rather only that a shift is evident in the community as a whole. We cannot conclusively rule out their presence because experimental and bioinformatics techniques can provide false negatives, but does indicate an underrepresentation of the organism in the selection of sequences analyzed in this current study that may be driven by biologic effects. As this is, to our knowledge, the first report of the gut microbiome composition in Jo18−/− mice, many follow-up experiments to examine the strain-level associations and related changes to the host and gut metabolism are warranted. We are also investigating whether alterations in self- or microbial lipids are involved in activation of iNKT cells.

Collectively, our data not only show an important role of iNKT cell subset activation in diet-induced progression from steatosis to fibrosis, but also a notable similarity with human NAFLD showing a significant increase in activation of iNKT cells in peripheral blood of NASH patients.

Acknowledgments
This work was performed with the support of the Flow Cytometry Core at the Veterans Affairs San Diego Health Care System and the San Diego Veterans Medical Research Foundation. We thank Gregory Humphrey, Cole Heale, and Tata Schwartz for sample processing and Gail Ackermann for assistance with metadata curation and data handling.

Disclosures
V.K. is a scientific cofounder of and a consultant for GRI-Bio, La Jolla, CA. The other authors have no financial conflicts of interest.

References
9. Marrero, L. R., Ware, and V. Kumar. 2015. Type II NKT cells in inflammation, autoimmunity, microbial immunity, and cancer. Front. Immunol. 6: 316.
NKT CELLS IN HEPATIC STEATOSIS AND FIBROSIS


Va´zquez-Baeza, Y., M. Pirrung, A. Gonzalez, and R. Knight. 2013. EMPeror: a

Guebre-Xabier, M., S. Yang, H. Z. Lin, R. Schwenk, U. Krzych, and


Immunity 51: 130–141.

Hepatology 59: 1830–1839.

Hepatology 143: 765–776.e3.


S. S. Majumdar, and P. Nagarajan. 2014. Role of immunodeficient animal

J. A. Navas-Molina, and R. Knight. 2017. Bringing the dynamic microbiome to


IMb. Commun. 9: 2146.

Hepatology 52: 1475–1486.

Hepatology 68: 918–932.


Hepatology 100: 10913–10918.

Hepatology 181: 4656–4665.

Hepatology 73: 1576–1585.


Hepatology 97: 4464–4472.


